Key result
Apatinib yields a three-month partial response in metastatic scalp angiosarcoma with KIT and KDR amplifications.
Why the study?
Metastatic or relapsed angiosarcoma has a poor prognosis and limited efficacy of conventional chemotherapy, prompting exploration of apatinib as a treatment option.
Does apatinib improve tumor response in a patient with advanced angiosarcoma?
Comparison
Apatinib treatment at daily doses of 250 to 725 mg
Design
Case report
Authors
Loading...
Caution against routine use from single case; hypothesis-generating for apatinib in KDR-amplified angiosarcoma.
Case Report (n=1)
No
Does apatinib improve tumor response in a patient with advanced angiosarcoma?
Apatinib may be a useful therapeutic option for patients with advanced angiosarcoma, potentially related to KDR gene amplification.
Yang et al. (2018) conducted a case report in KIT- and KDR-amplified angiosarcoma (n=1). Apatinib was evaluated on Tumor response. Apatinib treatment resulted in a partial response lasting three months in a patient with metastatic scalp angiosarcoma harboring KIT and KDR amplifications.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: